Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

Leukemia

Volumn 14, Issue 4, 2000, Pages 567-572

  McLeod, H L ^a   Krynetski, E Y ^b   Relling, M V ^b   Evans, W E ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

6 Mercaptopurine; Childhood acute lymphoblastic leukemia; Pharmacogenetics; Thiopurine methytransferase

Indexed keywords

MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLAST CELL; ENZYME ACTIVITY; ERYTHROCYTE; GENETIC POLYMORPHISM; METHYLATION; PRIORITY JOURNAL; REVIEW;

EID: 0034034158     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401723     Document Type: Review

References (34)

1. Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999; 93: 2817-2823.
2. McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM, Eden OB, Hall AG, Gibson BES. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999; 105: 696-700.
3. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharmaceut Res 1999; 16: 342-349.
4. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuelz JD, Relling MV Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 279-290.
5. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1990; 336: 225-229.
6. Evans WE, Horner M, Chu YO, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltranterase-deficient child with acute lymphoblastic leukemia. J Pediatr 1991; 119: 985-989.
7. McLeod HL, Miller DR, Evans WE. Azathioprine induced myelosuppression in thiopurine methyltransferase deficient heart-transplant recipient. Lancet 1993; 341: 1151.
8. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341: 436.
9. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharm Ther 1994; 55: 15-20.
10. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-516.
11. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, ParkHah JO, Iven H, Schmiegelow K, Branum E, Obrain J, Weinshilboum R. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73.
12. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, Evans WE. Thiopurine S-methyltransterase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1993; 58: 694-702.
13. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransterase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997; 94: 6444-6449.
14. delaMoureyre CSV, Debuysere H, Sabbagh N, Marez D, Vinner E, Chevalier ED, LoGuidice JM, Broly F. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998; 12: 177-185.
15. Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM. Human thiopurine methyltransferase pharmacogenetics - kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest 1998; 101: 1036-1044.
16. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92: 949-953.
17. Tai HL, Fessing MY, Bonten EJ, Yanishevsky Y, d'Azzo A, Krynetski EY, Evans WE. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT* 2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 1999; 9: 641-650.
18. Loennechen T, Yates CR, Fessing MY, Relling MV, Krynestski EY, Evans WE. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin Pharmacol Ther 1998; 64: 46-51.
19. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Gen 1999; 8: 371-376.
20. Ameyaw MM, Collie-Duguid ESR, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransterase alleles in British and Ghanaian populations. Hum Mol Gen 1999; 8: 367-370.
21. Collie-Duguid ESR, Prichard SC, Powrie RH, Sludden J, Collier DA, Li T, McLeod HL. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37-42.
22. McLeod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw MM, Powrie RH, Booth L, Collie-Duguid ESR. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan subjects. Pharmacogenetics 1999; 9: 773-776.
23. Kumagai K, Hiyama K, Ishioka S, Sato H, Yamanishi Y, McLeod HL, Konishi F, Maeda H, Yamakido M. Allelotype frequency of the thiopurine methyltransferase gene in Japanese. Pharmacogenetics (in press).
24. Coulthard SA, Howell C, Robson J, Hall AG. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood 1998; 92: 2856-2862.
25. delaMoureyre CSV, Debuysere H, Mastain B, Vinner E, Marez D, LoGuidice JM, Chevalier D, Brique S, Motte K, Colombel JF, Turck D, Noel C, Flipo EM, Pol A, Lhermitte M, Lafitte JJ, Libersa C, Broly F. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br Pharmacol 1998; 125: 879-887.
26. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-duguid ESR, Reid DM. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-718.
27. McLeod HL, Relling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic-leukemia. Blood 1995; 85: 1897-1902.
28. Relling MV, Hancock HL, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH Evans WE. Intolerance to mercaptopurine therapy related to heterozygosity at the thiopurine methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-2008.
29. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui CH. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354: 34-39.
30. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behn FG, Pui CH. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12: 346-352.
31. Thomsen JB, Schroder H, Kristinsson J, Madsen B, Szumlanski C, Weinshilboum R, Andersen JB, Schmiegelow. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Cancer 1999; 86: 1080-1086.
32. Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am Hum Genet 1998; 63: 11-16.
33. Kitchen BJ, Moser A, Lowe E, Balis FM, Widemann B, Anderson L, Strong J, Blaney SM, Berg SL, O'Brien M, Adamson PC. Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxythioguanine. J Pharmacol Exp Ther 1999; 2: 870-874.
34. Krynetski EY, Krynetskaia NF, Yanishevski Y, Evans WE. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol 1995; 6: 1141-1147.